(Q28538411)

English

Effect of amifostine in head and neck cancer patients treated with radiotherapy: a systematic review and meta-analysis based on randomized controlled trials

scientific article (publication date: 2014)

In more languages

Statements

scholarly article

0 references

1 reference

12 November 2019

systematic review

1 reference

PubMed publication ID

1 reference

PubMed publication ID

Effect of amifostine in head and neck cancer patients treated with radiotherapy: a systematic review and meta-analysis based on randomized controlled trials (English)

0 references

adaptive radiation therapy

1 reference

based on heuristic

inferred from title

squamous cell carcinoma

1 reference

12 November 2019

head and neck neoplasms

1 reference

19 June 2019

radiation sickness

1 reference

12 November 2019

randomized controlled trial

1 reference

19 September 2019

1 reference

12 November 2019

systematic review

1 reference

based on heuristic

inferred from title

head and neck cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

head and neck carcinoma

1 reference

based on heuristic

inferred from title

author name string

Jundong Gu

1

0 references

Siwei Zhu

2

0 references

Xuebing Li

3

0 references

Hua Wu

4

0 references

Yang Li

5

0 references

Feng Hua

6

0 references

language of work or name

0 references

publication date

2 May 2014

4 references

3 April 2019

19 June 2019

19 September 2019

12 November 2019

4 references

3 April 2019

19 June 2019

19 September 2019

12 November 2019

9

0 references

5

0 references

e95968

0 references

copyright license

Creative Commons Attribution 4.0 International

4 references

Europe PubMed Central

3 April 2019

Europe PubMed Central

19 June 2019

Europe PubMed Central

19 September 2019

Europe PubMed Central

12 November 2019

copyright status

0 references

on focus list of Wikimedia project

0 references

Impact of reporting bias in network meta-analysis of antidepressant placebo-controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008569

19 March 2017

Global cancer statistics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008569

19 March 2017

Measuring inconsistency in meta-analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008569

19 March 2017

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008569

19 March 2017

Meta-analysis in clinical trials

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008569

19 March 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008569

29 September 2017

Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008569

29 September 2017

Costs of treatment intensification for head and neck cancer: concomitant chemoradiation randomised for radioprotection with amifostine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008569

29 September 2017

Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008569

29 September 2017

Toxicity profile of intensity-modulated radiation therapy for head and neck carcinoma and potential role of amifostine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008569

29 September 2017

Pilot study of subcutaneous amifostine in patients undergoing postoperative intensity modulated radiation therapy for head and neck cancer: preliminary data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008569

29 September 2017

Amifostine: is there evidence of tumor protection?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008569

29 September 2017

Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008569

29 September 2017

Amifostine in clinical oncology: current use and future applications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008569

29 September 2017

Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008569

29 September 2017

Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008569

29 September 2017

Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008569

29 September 2017

Radiochemotherapy with amifostine cytoprotection for head and neck cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008569

29 September 2017

Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008569

3 June 2018

Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008569

3 June 2018

Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0095968

21 January 2018

Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0095968

21 January 2018

Phase II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) and amifostine (ethyol) in head and neck squamous cell carcinomas: A-3 protocol

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0095968

21 January 2018

A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0095968

21 January 2018

A prospective, nonrandomized study of the impact of amifostine on subsequent hypothyroidism in irradiated patients with head and neck cancers

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0095968

21 January 2018

The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0095968

21 January 2018

Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection?

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0095968

21 January 2018

Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0095968

21 January 2018

Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0095968

21 January 2018

Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0095968

21 January 2018

Does amifostine have a role in chemoradiation treatment?

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0095968

21 January 2018

Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008569

27 November 2018

Daily subcutaneous amifostine administration during irradiation of pediatric head and neck cancers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008569

27 November 2018

A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008569

27 November 2018

A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24788761

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hyperfractionated accelerated radiotherapy with concomitant integrated boost of 70-75 Gy in 5 weeks for advanced head and neck cancer. A phase I dose escalation study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24788761

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III randomized trial of amifostine as a radioprotector in head and neck cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24788761

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)

1 reference

https://pubmed.ncbi.nlm.nih.gov/24788761

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Daily amifostine given concomitantly to chemoradiation in head and neck cancer. A pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24788761

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: A prospective randomized study in squamous cell head and neck cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24788761

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24788761

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intensity-modulated radiotherapy in head and neck cancer: results of the prospective study GORTEC 2004-03

1 reference

https://pubmed.ncbi.nlm.nih.gov/24788761

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0095968

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

2014PLoSO...995968G

0 references

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PMC publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28538411&oldid=1732013535"